Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases

Rhea-AI Summary

Lilly (NYSE: LLY) has signed a definitive agreement to acquire Merida Biosciences, a biotechnology company developing precision biologics for serious autoimmune and allergic diseases. Merida’s antibody-engineering platform is designed to selectively and durably remove disease-causing antibodies while preserving normal immune function.

Merida’s lead asset, MER511, is in Phase 1 for Graves’ disease and thyroid eye disease, with initial data showing robust reductions in pathogenic thyroid-stimulating antibodies and a favorable initial safety profile. The pipeline also includes MER769, a preclinical program for food allergy, asthma, chronic spontaneous urticaria and other IgE‑driven diseases, plus earlier programs in kidney and other immune-mediated conditions.

According to Lilly, the deal is valued at up to $2.875 billion in cash, including an upfront payment and contingent milestone payments. The transaction is subject to customary closing conditions and regulatory approvals and is expected to close in the fourth quarter of 2026, after which it will be reflected in Lilly’s GAAP financial results and guidance.

Positive

• Acquisition value up to $2.875 billion in cash, including milestones
• MER511 Phase 1 data show robust reductions in pathogenic antibodies with favorable initial safety
• Pipeline expansion into Graves’ disease, thyroid eye disease, food allergy, asthma, urticaria, and kidney diseases
• Strengthens immunology capabilities and precision approach to antibody-driven diseases

Negative

• Transaction not yet closed, subject to regulatory approvals and customary conditions
• Financial impact unknown until Lilly determines GAAP accounting treatment after closing
• Large cash outlay of up to $2.875 billion including contingent milestones

Market Context

The acquisition-tag history averaged -0.11% across 5 events. This platform record adds context to Li...

Analysis

The acquisition-tag history averaged -0.11% across 5 events. This platform record adds context to Lilly's Merida announcement, while low short positioning and recent insider Net Selling remain relevant risk factors.

Key Figures

Maximum cash consideration: up to $2.875 billion Lead program phase: Phase 1 U.S. Graves' disease population: approximately 3 million people +2 more

5 metrics

Maximum cash consideration up to $2.875 billion Merida acquisition; upfront and contingent milestone payments

Lead program phase Phase 1 MER511 for Graves' disease and thyroid eye disease

U.S. Graves' disease population approximately 3 million people U.S. prevalence stated in the article

TED incidence among Graves' patients 25 to 40 percent People with Graves' disease who develop thyroid eye disease

Expected closing fourth quarter of 2026 Subject to customary closing conditions and regulatory approvals

Previous Acquisition Reports

5 past events · Latest: Jul 16 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 16	Mental-health acquisition	Positive	+1.1%	AtaiBeckley acquisition included upfront cash and contingent milestone consideration.
Jun 24	Sleep-disorder acquisition	Positive	+0.9%	Centessa acquisition expanded Lilly's sleep-wake disorder clinical portfolio.
May 26	Infectious-disease acquisitions	Positive	-0.0%	Three acquisitions expanded Lilly's infectious-disease prevention portfolio.
Apr 27	Myelofibrosis acquisition	Positive	-1.8%	Ajax acquisition added a Phase 1 JAK2 inhibitor program.
Apr 20	CAR-T acquisition	Positive	-0.8%	Kelonia acquisition broadened Lilly's in vivo CAR-T capabilities.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Acquisition-tagged announcements produced mixed reactions, with a historical average move of -0.11% and more negative than positive outcomes.

Key Terms

autoantibodies, thyroid-stimulating immunoglobulins, biologics, gaap

4 terms

autoantibodies medical

"selectively degrade pathogenic autoantibodies, the disease-causing agents"

Autoantibodies are proteins made by the immune system that mistakenly target a person’s own tissues, like friendly fire where soldiers attack their own team. They matter to investors because their presence influences diagnosis, disease progression, and patient safety, which can affect demand for drugs, diagnostic tests, trial outcomes, regulatory decisions, and potential liabilities in healthcare-related companies.

thyroid-stimulating immunoglobulins medical

"conditions driven by thyroid-stimulating immunoglobulins"

Antibodies produced by the immune system that bind to and activate the thyroid-stimulating hormone (TSH) receptor, causing the thyroid gland to produce excess thyroid hormones. Think of them as a biological key that falsely turns the thyroid ‘on.’ They matter to investors because they are a diagnostic marker and therapeutic target in autoimmune hyperthyroidism; their presence and levels can affect clinical trial endpoints, regulatory data, and the market for related diagnostics and treatments.

biologics medical

"Merida is developing biologics engineered to selectively degrade"

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

gaap financial

"accordance with Generally Accepted Accounting Principles (GAAP)"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Merida's antibody-engineering platform is designed to enable precise, durable removal of disease-causing antibodies, while preserving normal immune function

Initial Phase 1 data show MER511 achieved robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile

Acquisition strengthens Lilly's immunology capabilities and its opportunity to elevate the standard of care for immune-mediated conditions with high unmet need 

INDIANAPOLIS and CAMBRIDGE, Mass., Aug. 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc. (Merida), a biotechnology company advancing a new class of precision therapeutics for serious autoimmune and allergic diseases, today announced a definitive agreement for Lilly to acquire Merida.

Merida is developing biologics engineered to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. The precision degradation approach is intended to address the biological cause of these diseases, rather than broadly suppressing the immune system, as many current therapies do.

Merida's lead program, MER511, is in Phase 1 development for Graves' disease and thyroid eye disease (TED), conditions driven by thyroid-stimulating immunoglobulins, which are autoantibodies that activate the thyroid-stimulating hormone receptor. Graves' disease affects approximately 3 million people in the U.S., and patients face elevated cardiovascular risk and mortality. Roughly 25 to 40 percent of people with Graves' disease go on to develop TED, which can cause pain, disfigurement, and in severe cases, vision loss. While there are approved treatments for both conditions, none directly target the autoantibodies that cause them. Because pathogenic autoantibodies drive a wide range of serious diseases, Merida's platform has potential application well beyond its lead program. The company's pipeline also includes MER769, a preclinical program focused on food allergy, asthma, chronic spontaneous urticaria and other diseases driven by the antibody responsible for triggering allergic reactions, along with earlier-stage programs in kidney diseases such as membranous nephropathy and other immune-mediated conditions.

"We're building our pipeline around therapies that meaningfully change the course of disease, not just its downstream effects. Merida's lead program is designed to do exactly that: selectively and directly eliminating the autoantibodies causing Graves' disease and thyroid eye disease, while preserving normal immune function, with initial Phase 1 data already pointing to the potential for improved efficacy and safety," said Francisco Ramírez-Valle, M.D., Ph.D., senior vice president, Lilly immunology research and early clinical development. "We see potential to apply this precision approach across a broad range of antibody-driven diseases, and we look forward to advancing this novel technology working with the Merida team." 

"Merida was founded to fundamentally change how autoimmune and allergic diseases are treated, by targeting the antibodies driving them directly, rather than suppressing the immune system broadly. Under our CSO and founder Dario Gutierrez's scientific leadership, our team has advanced that idea from concept to clinical data, and what we've seen so far reinforces our conviction that this approach can make a meaningful difference for patients," said Adam Townsend, chief executive officer of Merida. "Today's announcement reflects the hard work of the entire Merida team, and joining Lilly gives our science the resources and commitment to realize its potential for patients with immune-mediated conditions."

Under the terms of the agreement, Lilly will acquire Merida and pay up to $2.875 billion in cash, inclusive of an upfront payment, and contingent milestone payments.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026. Lilly will determine the accounting treatment of this transaction in accordance with Generally Accepted Accounting Principles (GAAP) upon closing. This transaction will thereafter be reflected in Lilly's financial results and financial guidance.

Ropes & Gray LLP is acting as legal counsel to Lilly. Centerview Partners LLC is acting as an exclusive financial advisor, and Goodwin Procter LLP is acting as legal counsel to Merida.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

About Merida Biosciences
Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers. This approach, enabled by advances in protein engineering and immunology, has the potential to address numerous autoimmune and allergic conditions that are inadequately treated today. Please visit www.meridabio.com to learn more.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Merida and Merida's product candidates for immune-mediated diseases, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in closing and implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will close the transaction or realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this release, or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:	Megan Talon, megan.talon@lilly.com (Media)
	Michael Czapar, czapar_michael_c@lilly.com (Investors)
	Cynthia Clayton, cynthia@claytonbiocomms.com (Merida Media)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-to-acquire-merida-biosciences-to-advance-treatments-for-serious-autoimmune-and-allergic-diseases-302864686.html

SOURCE Eli Lilly and Company

FAQ

What did Lilly (LLY) announce about acquiring Merida Biosciences on August 31, 2026?

Lilly announced a definitive agreement to acquire Merida Biosciences for up to $2.875 billion in cash. According to Lilly, the deal includes an upfront payment and contingent milestone payments, aiming to strengthen its immunology portfolio in autoimmune and allergic diseases.

How much is Lilly (LLY) paying to acquire Merida Biosciences and how is it structured?

Lilly will pay up to $2.875 billion in cash to acquire Merida Biosciences. According to Lilly, this total includes an upfront payment plus additional contingent milestone payments, with the final amount depending on achievement of specified development or commercial milestones.

When is the Lilly (LLY) acquisition of Merida Biosciences expected to close?

The Merida Biosciences acquisition by Lilly is expected to close in the fourth quarter of 2026. According to Lilly, completion is subject to customary closing conditions, including required regulatory approvals, after which the transaction will be reflected in its financial results and guidance.

What is Merida Biosciences’ lead program MER511 that Lilly (LLY) is acquiring?

MER511 is Merida’s Phase 1 lead program for Graves’ disease and thyroid eye disease. According to Lilly, initial Phase 1 data show robust reductions in pathogenic thyroid-stimulating antibodies with a favorable initial safety profile, targeting the autoantibodies driving these conditions directly.

How does the Merida Biosciences acquisition support Lilly’s (LLY) immunology strategy?

The acquisition adds a precision antibody-degradation platform targeting disease-causing autoantibodies. According to Lilly, Merida’s programs, including MER511 and preclinical asset MER769, expand its opportunity to elevate care for immune-mediated, antibody-driven conditions beyond broad immune suppression approaches.

What other pipeline assets besides MER511 does Merida bring to Lilly (LLY)?

Merida’s pipeline includes MER769, a preclinical program for food allergy, asthma, chronic spontaneous urticaria and other IgE-driven diseases. According to Lilly, Merida also has earlier-stage programs in kidney diseases like membranous nephropathy and additional immune-mediated conditions.

How will the Merida Biosciences acquisition affect Lilly’s (LLY) financial reporting?

Lilly will determine the accounting treatment for the Merida acquisition under GAAP upon closing. According to Lilly, the transaction will then be incorporated into its financial results and financial guidance, but specific earnings or balance sheet impacts were not detailed in the announcement.